A Phase 1/2a, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 In Combination with Anti-PD-1 (pembrolizumab) In Patients With, Locally Advanced or Metastatic Solid Tumors

This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy.

The study is comprised of two groups; dose optimization and dose expansion cohorts.

Dose Optimization included first-line and second-line advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC)

The dose expansion cohort will include first-line NSCLC patients.